Armand Cacciarelli, MD
Gastroenterology · New York, NYNPI 1962489880
Payments from drug & device makers
Across 79 payments — averaging $22.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$798
- Takeda Pharmaceuticals U.S.A., Inc.$320
- QOL Medical, LLC$183
- Lilly USA, LLC$104
- Bristol Myers Squibb$100
- Merck$74
- plus $195 from 6 others
Across 1 payment — averaging $1500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2K
What the payments were for
- Food & beverage$1,74799%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 36 | $798 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $320 |
| QOL Medical, LLC | 5 | $183 |
| Lilly USA, LLC | 6 | $104 |
| Bristol Myers Squibb | 5 | $100 |
| Merck | 3 | $74 |
| Regeneron Healthcare Solutions, Inc. | 2 | $59 |
| Johnson & Johnson | 1 | $35 |
| Pfizer | 1 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Sucraid$125
How this compares
$1,773 in reported general payments places this provider in the 45th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mesalamine | 22 | $8,769 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 166 | $3,202 |
| Famotidine | 194 | $1,520 |
| Omeprazole | 148 | $1,427 |
| Pantoprazole Sodium | 66 | $470 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 34 | $450 |
| Procto-Med HcHydrocortisone | 15 | $313 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 11 | $239 |
| Hydrocortisone | 11 | $168 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in New York
- David HudesmanNew York$3.6M
- Ellen ScherlNew York$2.9M
- Bruce SandsNew York$2.8M
- Arun SwaminathNew York$2.7M
- Sonal KumarNew York$2.3M
- David Carr LockeNew York$2.1M
- Arthur KornbluthNew York$1.9M
- Ira JacobsonNew York$1.8M
- James MarionNew York$1.7M
- Jean Frederick ColombelNew York$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.